Tetra Radar · Company Timeline
Rocket Pharmaceuticals Inc (RCKT)
Sector: Health Care
Earlier observations
- · FDA approval. The FDA approved KRESLADI for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen (HLA)-matched sibling donor for allogeneic hematopoietic stem cell transplant.
Observations from the last 30 days, with Clusters and Heat Signatures, are in the Tetra Radar Library.
Dates are event dates. Tetra Radar observes public information for research purposes. It does not provide investment advice.